AbbVie (NYSE: ABBV) reported Q2 EPS of $2.00, $0.03 better than the analyst estimate of $1.97. Revenue for the quarter came in at $8.28 billion versus the consensus estimate of $8.21 billion.

GUIDANCE:

AbbVie sees FY2018 EPS of $7.76-$7.86, versus the consensus of $7.81.

For earnings history and earnings-related data on AbbVie (ABBV) click here.